Precigen (PGEN) Net Equity Issued and Repurchased (2012 - 2025)
Precigen (PGEN) posted quarterly Net Equity Issued and Repurchased of -$355000.0 for Q1 2025, up 40.44% quarter-over-quarter from -$596000.0 in Q4 2024.
Precigen (PGEN) Net Equity Issued and Repurchased (2012 - 2025) Analysis & Trends
Precigen (PGEN) has reported Net Equity Issued and Repurchased for 8 consecutive years, with -$355000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$355000.0; the TTM figure through Dec 2025 stood at -$355000.0 (down 101.14% YoY), while the FY2025 annual figure was -$355000.0, down 101.14% from the prior year.
- Net Equity Issued and Repurchased climbed to -$355000.0 in Q1 2025 per PGEN's latest filing, from -$596000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $121.0 million in Q1 2021 and bottomed at -$693000.0 in Q2 2023.
- Historically, Net Equity Issued and Repurchased has averaged $37.5 million across 4 years, with a median of $15.7 million in 2024.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 245.84% in 2021 and fell as far as 245.84% in 2021.
- Precigen's Net Equity Issued and Repurchased stood at $121.0 million in 2021, then slumped by 100.57% to -$693000.0 in 2023, then increased by 14.0% to -$596000.0 in 2024, then soared by 40.44% to -$355000.0 in 2025.
- Business Quant data shows PGEN's Net Equity Issued and Repurchased at -$355000.0 in Q1 2025, -$596000.0 in Q4 2024, and $31.8 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -355,000.00 |
| Mar 31, 2025 | -355,000.00 |
| Dec 31, 2024 | -596,000.00 |
| Dec 31, 2024 | -596,000.00 |
| Sep 30, 2024 | 31.83 Mn |
| Sep 30, 2024 | 31.83 Mn |
| Jun 30, 2023 | -693,000.00 |
| Jun 30, 2023 | -693,000.00 |
| Mar 31, 2023 | 73.50 Mn |
| Mar 31, 2023 | 73.50 Mn |
| Mar 31, 2021 | 121.05 Mn |
| Mar 31, 2021 | 121.05 Mn |
| Mar 31, 2020 | 35.00 Mn |
| Mar 31, 2020 | 35.00 Mn |
| Sep 30, 2015 | 218.19 Mn |
| Sep 30, 2015 | 218.19 Mn |
| Mar 31, 2015 | 110.04 Mn |
| Mar 31, 2015 | 110.04 Mn |
| Dec 31, 2013 | -150.00 Mn |
| Dec 31, 2013 | -150.00 Mn |